<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 08 May 2021 07:19:34 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>迈向未来: 肿瘤的精准治疗时代</title><link>https://mp.weixin.qq.com/s/ne_01LHDHCMI9Yh6Pt9G6g</link><description></description><content:encoded><![CDATA[迈向未来: 肿瘤的精准治疗时代]]></content:encoded><pubDate>Sat, 08 May 2021 06:43:09 +0800</pubDate></item><item><title>百济神州：优秀的Biotech，坎坷的Big Pharma</title><link>https://mp.weixin.qq.com/s/7tlnLgVKtONecO76DvDs_w</link><description></description><content:encoded><![CDATA[百济神州：优秀的Biotech，坎坷的Big Pharma]]></content:encoded><pubDate>Fri, 07 May 2021 07:06:01 +0800</pubDate></item><item><title>恒瑞医药：抗体研发管线</title><link>https://mp.weixin.qq.com/s/Dlr9VAcrG5taAMd9T2xtPw</link><description></description><content:encoded><![CDATA[恒瑞医药：抗体研发管线]]></content:encoded><pubDate>Thu, 06 May 2021 06:55:25 +0800</pubDate></item><item><title>辉瑞公司mRNA疫苗制造过程首次揭秘</title><link>https://mp.weixin.qq.com/s/HKqOZmNILtTCyVgtbVv6sA</link><description></description><content:encoded><![CDATA[辉瑞公司mRNA疫苗制造过程首次揭秘]]></content:encoded><pubDate>Wed, 05 May 2021 07:14:58 +0800</pubDate></item><item><title>人类的希望！一文读懂mRNA疫苗</title><link>https://mp.weixin.qq.com/s/h-AnhV2Eos7OTo2MD3lS7g</link><description></description><content:encoded><![CDATA[人类的希望！一文读懂mRNA疫苗]]></content:encoded><pubDate>Wed, 05 May 2021 07:14:58 +0800</pubDate></item><item><title>双抗深度报告：双抗作用机制梳理</title><link>https://mp.weixin.qq.com/s/-H7xVZI5O61xp6lZgnuJjw</link><description></description><content:encoded><![CDATA[双抗深度报告：双抗作用机制梳理]]></content:encoded><pubDate>Tue, 04 May 2021 07:29:10 +0800</pubDate></item><item><title>双抗深度报告：双抗概念、分类及技术平台梳理</title><link>https://mp.weixin.qq.com/s/cNZwzvtVo3jyzMi9_ycYfA</link><description></description><content:encoded><![CDATA[双抗深度报告：双抗概念、分类及技术平台梳理]]></content:encoded><pubDate>Mon, 03 May 2021 10:12:57 +0800</pubDate></item><item><title>庆祝创号一周年，五一福利大放送！！！</title><link>https://mp.weixin.qq.com/s/C7B_pYMjBvt-1G3RJzioQQ</link><description></description><content:encoded><![CDATA[庆祝创号一周年，五一福利大放送！！！]]></content:encoded><pubDate>Sun, 02 May 2021 07:41:49 +0800</pubDate></item><item><title>个性化新抗原肿瘤疫苗的研究进展和挑战</title><link>https://mp.weixin.qq.com/s/HTF1G0v0Xal2NCVfzhazbg</link><description></description><content:encoded><![CDATA[个性化新抗原肿瘤疫苗的研究进展和挑战]]></content:encoded><pubDate>Sat, 01 May 2021 18:57:12 +0800</pubDate></item><item><title>FDA对3款PD-(L)1的6项加速批准“再审”</title><link>https://mp.weixin.qq.com/s/zuD2jSYlhhCzopWd1nLUfA</link><description></description><content:encoded><![CDATA[FDA对3款PD-(L)1的6项加速批准“再审”]]></content:encoded><pubDate>Fri, 30 Apr 2021 19:32:44 +0800</pubDate></item><item><title>Her2之后，正在内卷的Claudin 18.2！</title><link>https://mp.weixin.qq.com/s/-E4RTiPPZmLIixFCuYMEag</link><description></description><content:encoded><![CDATA[Her2之后，正在内卷的Claudin 18.2！]]></content:encoded><pubDate>Thu, 29 Apr 2021 19:30:05 +0800</pubDate></item></channel></rss>